Application of methazolamide in preparation of medicine for treating type 1 diabetic cardiomyopathy

A technology of type 1 diabetes and methazolamide is applied in the application field of methazolamide in the preparation of medicines for the treatment of type 1 diabetic cardiomyopathy, and can solve the problems of lack of specific drug treatment and the like

Pending Publication Date: 2021-05-11
GUANGZHOU MEDICAL UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Effective blood sugar control is the basic method for the treatment of DCM, combined with the control of blood lipids, b...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methazolamide in preparation of medicine for treating type 1 diabetic cardiomyopathy
  • Application of methazolamide in preparation of medicine for treating type 1 diabetic cardiomyopathy
  • Application of methazolamide in preparation of medicine for treating type 1 diabetic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1 The effect test of methazolamide of the present invention in the treatment of type 1 diabetic cardiomyopathy

[0020] 1. Experimental method

[0021] 1. Drugs and drug preparation

[0022] Methazolamide (Selleck)

[0023] Streptozotocin (Sigma-Aldrich)

[0024] Prepare streptozotocin solution with citrate buffer (0.1M, pH 4.5); with 2% DMSO: 30% PEG300: 2% Tween80: ddH 2 O solvent to prepare methazolamide solution.

[0025] 2. Animals and Grouping

[0026] C57BL / 6J mice (8 weeks, 20±2 g) were raised at 22±3° C., 50-70% humidity, and had free access to food and water. They were randomly divided into two groups: control group (Control) and diabetes group (T1DM). After one week of adaptation, mice in T1DM group were injected intraperitoneally with 45 mg / kg / d streptozotocin solution for 6 days. Mice with random blood glucose levels ≥ 16.7 mM were considered to have type 1 diabetes mellitus (T1DM) 3 days after completion of the injection. Mice in the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new application of methazolamide, and particularly relates to a new application of methazolamide in preparation of a medicine for treating type 1 diabetic cardiomyopathy. In the research, the inventor of the application finds that the methazolamide can reduce the blood sugar of the type 1 diabetic cardiomyopathy, improve the heart morphological structure abnormality and cardiac contraction and diastolic dysfunction of the type 1 diabetic cardiomyopathy, can improve myocardial hypertrophy caused by high glucose, and has a good treatment effect on the type 1 diabetic cardiomyopathy. The invention provides a new drug choice for the treatment of type 1 diabetic cardiomyopathy.

Description

technical field [0001] The invention relates to a new application of methazolamide, in particular to a new application of methazolamide in treating type 1 diabetic cardiomyopathy. Background technique [0002] Diabetes mellitus (DM) is a chronic disease that occurs when the body cannot secrete or not secrete enough insulin or cannot effectively use insulin, resulting in elevated glucose levels in the blood. Diabetes is a growing global problem. According to the latest report of the International Diabetes Federation, about 425 million people (20-79 years old) worldwide suffer from diabetes, with a prevalence rate of 8.8%, and it is expected to reach 9.9% (about 629 million) by 2045; and, in 2017, about Four million adults (aged 20-79) die from diabetes, accounting for 10.7% of global deaths. One of the most common and serious complications of diabetes is diabetic cardiomyopathy. Diabetic cardiomyopathy (DCM) is a lesion of abnormal myocardial structure and function in diab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/433A61P3/10A61P9/00A61P9/04
CPCA61K31/433A61P3/10A61P9/00A61P9/04
Inventor 侯宁袁文常陈晓晴李逸朗李从林蔡佳璇练宇玲
Owner GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap